Topical Ocular BL1332 low dose

Phase 2Small molecule

BBausch & Lomb Incorporated

Topical Ocular BL1332 low dose is one of 5 small molecule programs targeting Ocular pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular PainActive, not recruiting

Ocular PainPhase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Ocular Pain

#DrugCompanyPhaseTrials

Toradol

Roche

Approved

—2

Dexycu

EEyePoint Pharmaceuticals, Inc.

Phase 3

2 3

Lotemax

BBausch & Lomb Incorporated

SYL1001

2 5

Topical Ocular BL1332 low dose

BBausch & Lomb Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Ocular Pain

NCT07412496

Clinical

Trials by Indication[1]

Ocular pain1 trial

A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy

Not yet recruiting·BBausch & Lomb Incorporated·Phase 2·NCT07412496·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical Ocular BL1332 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical Ocular BL1332 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical Ocular BL1332 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bausch & Lomb Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBausch & Lomb Incorporated

Topical Ocular BL1332 low dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Ocular pain1 trial

References

Drug Info

Quick Facts

Related News